Adberrahmane Laadem

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, Uwe Platzbecker, Ulrich Germing et al. · Blood · 2015 · 27 citations

Medicine, Hematology, Pharmacotherapy +15

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

Maria Domenica Cappellini, John B. Porter, Raffaella Origa et al. · Blood · 2013 · 15 citations

Medicine, Pharmacology, Pharmacotherapy +8

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Uwe Platzbecker, Ulrich Germing, Aristoteles Giagounidis et al. · Blood · 2014 · 12 citations

Medicine, Hematology, Internal Medicine +13

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Antonio Piga, Silverio Perrotta, Angela Melpignano et al. · Blood · 2014 · 11 citations

Medicine, Hematology, Iron Metabolism Disorders +12